http://www.reutershealth.com/archive/2002/04/12/eline/links/20020412elin005.html
Are everyday problems being dubbed 'disease'?
By Amy Norton
NEW YORK, Apr 12 (Reuters Health) - Recent medical advances and
the accompanying flood of new drugs for a range of ills threaten to "medicalize"
every human condition and behavior, according to some experts.
And, they say, the advent of genetic screening could eventually mean that
apparently healthy people will be labeled "sick" decades before an actual
diagnosis.
In an issue of the British Medical Journal dedicated to the topic of "medicalization,"
international researchers look at the pros and cons of screening for
disease-related genes, direct-to-consumer drug advertising and what some see as
the modern-day phenomenon of treating everyday problems--from balding heads to
unremarkable performance in the bedroom--as medical conditions in need of
treatment.
As part of the special issue, the journal polled readers on what they thought
were the top current "non-diseases." Among the most popular were baldness,
freckles, cellulite, penis envy and road rage. The number-one vote-getter was
"aging."
Some call it "disease mongering." In one article, Ray Moynihan, a journalist
with Australian Financial Review, and co-authors describe what they see as
"informal alliances" among drug companies and some doctors and consumer groups.
They argue that drug companies provide medical experts and patient groups offer
"victims" to attest to a given condition's severity and draw attention to a new
"breakthrough" treatment.
The authors also point to several examples--such as hair loss and excessive
shyness--of what can be regarded as normal human conditions that have been made
medical conditions because there is a pill available for them.
In another article, Barbara Mintzes of the University of British Columbia in
Vancouver, Canada, argues that prescription-drug advertising to
consumers--currently allowed only in the US and New Zealand--is helping to
medicalize "normal human experience."
"Relatively healthy people are targeted," she writes, "because of the need
for adequate returns on costly advertising campaigns."
Many of these advertising dollars, according to Mintzes, are spent on
relatively new, expensive drugs intended for long-term use in large groups of
people, such as medications for cholesterol,
impotence and anxiety.
And while studies prove these drugs work, the ads for them tend to target a
wider audience than the evidence supports, Mintzes said in an interview with
Reuters Health.
She cited cholesterol-lowering drugs as an example, saying that the evidence
that they cut heart disease death risk is "much better" for patients with
existing heart disease. But ads, Mintzes noted, are targeted at a much broader
population.
In a counterpoint to Mintzes' article, officials with the Whitehouse Station,
New Jersey-based drug company Merck argue that consumer advertising helps the
public make informed choices about their health and treatment.
And evidence shows there is under-diagnosis of many major diseases and
disease risk factors for which treatment exists, according to Silvia Bonaccorso
and Jeffrey Sturchio.
But Mintzes argued that advertisers and public health experts often have
different views on what ailments need "awareness raising."
Others say that as medicine has forayed into advertising, it has also gotten
deeply involved in people's sex lives. When it was launched in 1998, the
impotence drug
Viagra "became the world's most popular medicinal drug ever," write Graham
Hart and Kaye Wellings.
And while many men with
erectile dysfunction are thankful for the little blue pill, they add, using
an "overly medical" approach to sex threatens to ignore the relationship
dynamics and other factors that go into sexual behavior.
The UK public health experts note that forms of gynecological surgery aimed
at enhancing sexual pleasure have recently emerged. And in the US, about one
third of men and even more women now say they've had sexual dysfunction--a sign,
Hart and Wellings say, of a new obsession with sexual gratification and feelings
of inadequacy.
Hart, of the University of Glasgow, told Reuters Health that his concern is
that the term "sexual dysfunction" is being used to cover a range of behaviors
or feelings that may be natural for some people--such as a libido that's lower
than it used to be.
"If people are in happy, loving relationships in which, over time, sex plays
a less important part, this should not be seen as problematic or dysfunctional,"
he said.
Looking a bit into the future, UK genetics researchers say that genetic tests
"could drive a new wave" of medicalization. With the exception of a relatively
small number of medical conditions directly caused by a single defective gene,
genetic screening cannot predict whether a person will develop a disease, note
David Melzer, of the University of Cambridge, and Ron Zimmern, of Strangeways
Research Laboratory in Cambridge.
With diseases with multiple underlying factors--including major killers like
heart disease and cancer--screening for disease-related gene variations can only
give people information on their statistical risks, Melzer and Zimmern write.
"Genetic tests for markers that may not result in symptoms for half a century
or more could be new examples of a process of premature medicalization--of
attaching the 'disease' label before it has been established that prevention or
treatment is clearly beneficial," they argue.
Genetic technologies, the authors write, could be a "major benefit to
society, but their introduction must be measured...and, most importantly, based
on best evidence."
SOURCE: British Medical Journal 2002;324:863-864, 883-885,
886-891, 896-900, 908-911.
Copyright © 2002 Reuters Limited. All rights reserved.
Republication or redistribution of Reuters content, including by framing or
similar means, is expressly prohibited without the prior written consent of
Reuters. Reuters shall not be liable for any errors or delays in the content, or
for any actions taken in reliance thereon. Reuters and the Reuters sphere logo
are registered trademarks and trademarks of the Reuters group of companies
around the world.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.